Ross C. Klingsberg

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Harry Heijerman, Edward F. McKone, D.G. Downey et al. · The Lancet · 2019 · 1.4K citations · Full text

Life Sciences, Genetics, Pharmacology +14

Abrogation of TGF-β1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition

Weichao Guo, Bin Shan, Ross C. Klingsberg et al. · American Journal of Physiology-Lung Cellular and Molecular Physiology · 2009 · 217 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +13

Requirement of HDAC6 for Transforming Growth Factor-β1-induced Epithelial-Mesenchymal Transition

Bin Shan, Tso‐Pang Yao, Hong T. Nguyen et al. · Journal of Biological Chemistry · 2008 · 173 citations · Full text

Medicine, Cell Biology, Oncology +16

The Epstein-Barr Virus Latent Membrane Protein 1 and Transforming Growth Factor–β1 Synergistically Induce Epithelial–Mesenchymal Transition in Lung Epithelial Cells

Mark D Sides, Ross C. Klingsberg, Bin Shan et al. · American Journal of Respiratory Cell and Molecular Biology · 2010 · 66 citations

Life Sciences, Cell Biology, Molecular Biology +9

Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials

Ahmet Uluer, Gordon MacGregor, Pilar Azevedo et al. · The Lancet Respiratory Medicine · 2023 · 64 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9